Lead Sponsor

National and Kapodistrian University of Athens

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Age \>18 years
•2. Confirmed SARS-CoV2 infection by PCR of the nasal/pharyngeal swab, sputum, BAL
•3. Onset of the disease symptoms no more than 12 days before the inclusion of the patients in the trial
•4. Severe COVID-19 infection as determined with one of the following:
•* Respiratory rate 30/min
•* Oxygen Hemoglobin Saturation SAT 93
•* CRP \>1.5 (upper normal limit \<0.5)
•* Ferritin value \>100
•* Ratio of PaO2:FiO2 \<300mmHg
•* Pulmonary infiltrates in Chest X-Ray or Chest CT scan \>50% during 24-48 hours
•5. Life threatening infection as determined by one of the following:
•* Respiratory failure
•* Septic Shock
•* Multiple organ failure
•6. Signature of informed consent by the patient or legal representative Patients fulfilling criteria 1, 2, 3, 6 and one of criteria 4 or 5 will be eligible for the study.

•1. Critical illness due to progressive COVID-19 with expected survival time \<48 hours
•2. Intubated patients \>72 hours
•3. Chronic Heart failure NYHA 3 and/or preexisting left ventricular ejection fraction 30%
•4. Cardiovascular failure requiring 0.5μg/Kg/min nor-adrenaline or equivalent or more than 2 types of vasopressor medication
•5. Liver Cirrhosis Child C
•6. Liver failure with bilirubin \>5X ULN and increase of ALT/AST (at least one \>10X ULN)
•7. Previous history of allergic reaction to blood or blood products transfusion
•8. Known IgA deficiency
•9. Pregnancy
•10. Breast feeding women
•11. Pulmonary edema

Related studies

NCT05101213 · Adenovirus Infection, BK Virus Infection, and more

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

NCT05022446 · COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, and more

NCT04491292 · COVID-19 Infection

NCT06381739 · COVID-19 Infection

Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection